KR102627266B1 - 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드 - Google Patents

암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드 Download PDF

Info

Publication number
KR102627266B1
KR102627266B1 KR1020197025958A KR20197025958A KR102627266B1 KR 102627266 B1 KR102627266 B1 KR 102627266B1 KR 1020197025958 A KR1020197025958 A KR 1020197025958A KR 20197025958 A KR20197025958 A KR 20197025958A KR 102627266 B1 KR102627266 B1 KR 102627266B1
Authority
KR
South Korea
Prior art keywords
oxo
carboxamide
dihydropyridazine
chlorophenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197025958A
Other languages
English (en)
Korean (ko)
Other versions
KR20190115460A (ko
Inventor
일로나 구쳐
울리케 뢴
노르베르트 슈메스
루드비크 초른
라르스 뢰제
벤자민 바더
크리스티나 코버
라파엘 카레테로
데틀레프 스퇴키그트
호르스트 이를바혀
미카엘 플라텐
Original Assignee
바이엘 악티엔게젤샤프트
바이엘 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 악티엔게젤샤프트, 바이엘 파마 악티엔게젤샤프트 filed Critical 바이엘 악티엔게젤샤프트
Publication of KR20190115460A publication Critical patent/KR20190115460A/ko
Application granted granted Critical
Publication of KR102627266B1 publication Critical patent/KR102627266B1/ko
Assigned to 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 reassignment 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 권리의 전부이전등록 Assignors: 바이엘 악티엔게젤샤프트, 바이엘 파마 악티엔게젤샤프트
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197025958A 2017-02-09 2018-02-02 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드 Active KR102627266B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17155406.6 2017-02-09
EP17155406 2017-02-09
EP17202882.1 2017-11-21
EP17202882 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20190115460A KR20190115460A (ko) 2019-10-11
KR102627266B1 true KR102627266B1 (ko) 2024-01-24

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025958A Active KR102627266B1 (ko) 2017-02-09 2018-02-02 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드

Country Status (39)

Country Link
US (3) US12522594B2 (https=)
EP (1) EP3580211B1 (https=)
JP (1) JP7128826B2 (https=)
KR (1) KR102627266B1 (https=)
CN (3) CN110678459B (https=)
AU (1) AU2018217860B2 (https=)
BR (1) BR112019016497A2 (https=)
CA (1) CA3052718A1 (https=)
CL (1) CL2019002255A1 (https=)
CO (1) CO2019008684A2 (https=)
CR (1) CR20190364A (https=)
CU (1) CU24564B1 (https=)
CY (1) CY1124484T1 (https=)
DK (1) DK3580211T3 (https=)
DO (1) DOP2019000206A (https=)
EC (1) ECSP19057713A (https=)
ES (1) ES2847162T3 (https=)
GE (2) GEAP202115183A (https=)
HR (1) HRP20210143T1 (https=)
HU (1) HUE053191T2 (https=)
IL (1) IL268469B (https=)
JO (1) JOP20190193B1 (https=)
LT (1) LT3580211T (https=)
MA (1) MA47447B1 (https=)
MX (1) MX2019009571A (https=)
MY (1) MY198510A (https=)
NI (1) NI201900085A (https=)
PE (1) PE20191496A1 (https=)
PH (1) PH12019501846A1 (https=)
PL (1) PL3580211T3 (https=)
RS (1) RS61401B1 (https=)
SA (1) SA519402422B1 (https=)
SG (1) SG11201907232XA (https=)
SI (1) SI3580211T1 (https=)
TW (1) TWI770113B (https=)
UA (1) UA124507C2 (https=)
UY (1) UY37606A (https=)
WO (1) WO2018146010A1 (https=)
ZA (1) ZA201905902B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025227A1 (en) * 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP7128826B2 (ja) 2017-02-09 2022-08-31 バイエル・アクチエンゲゼルシヤフト がん治療のための２－ヘテロアリール－３－オキソ－２，３－ジヒドロピリダジン－４－カルボキサミド類
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
JP2023505907A (ja) 2019-12-16 2023-02-13 バイエル・アクチエンゲゼルシヤフト Ａｈｒインヒビターとｐｄ１インヒビター抗体との組合せおよび癌の治療におけるその使用
US20230279000A1 (en) 2020-02-26 2023-09-07 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
CN115397818A (zh) * 2020-03-27 2022-11-25 东亚St株式会社 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
JP2024535019A (ja) * 2021-09-14 2024-09-26 アライアンテラ（スーヂョウ）バイオファーマシューティカル・カンパニー・リミテッド ２－アリール又はヘテロアリール－３－オキソ－４－カルバミド－６－環状－ジヒドロピラジンアリール炭化水素受容体モジュレータ並びに疾患及び障害の治療におけるそれらの使用
EP4419685A1 (en) 2021-10-20 2024-08-28 University of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080056A2 (en) 2006-12-21 2008-07-03 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
CA2340230C (en) * 1998-08-14 2008-03-11 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives having cell adhesion inhibiting activity
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
CA2742411A1 (en) 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
WO2007040565A2 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
US20090048258A1 (en) 2005-02-01 2009-02-19 Masaki Ogino Amide Compound
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
ES2421191T3 (es) 2006-05-03 2013-08-29 Symrise Ag Antagonistas del receptor de Ah
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
ES2534199T3 (es) 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
BR112013002079B1 (pt) 2010-07-27 2021-09-14 Trustees Of Boston University Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
CA3025227A1 (en) * 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP7128826B2 (ja) * 2017-02-09 2022-08-31 バイエル・アクチエンゲゼルシヤフト がん治療のための２－ヘテロアリール－３－オキソ－２，３－ジヒドロピリダジン－４－カルボキサミド類
JP7167146B2 (ja) 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
EP3713922A1 (en) 2017-11-21 2020-09-30 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CA3082858A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
EP3713931B1 (en) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019101641A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
WO2020061377A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
WO2020102506A1 (en) 2018-11-14 2020-05-22 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics
IL290445B1 (en) 2019-08-12 2026-02-01 Bayer Ag [4,2,1]Triazolo[5,1-c]quinazolin-5-amines
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080056A2 (en) 2006-12-21 2008-07-03 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds

Also Published As

Publication number Publication date
HUE053191T2 (hu) 2021-06-28
US11795164B2 (en) 2023-10-24
GEAP202115183A (en) 2021-04-12
PH12019501846A1 (en) 2020-03-09
MY198510A (en) 2023-09-01
NI201900085A (es) 2019-11-15
IL268469A (en) 2019-09-26
BR112019016497A2 (pt) 2022-05-10
DK3580211T3 (da) 2021-01-25
CN116531380A (zh) 2023-08-04
GEP20217281B (en) 2021-08-10
CO2019008684A2 (es) 2019-08-20
CN110678459B (zh) 2023-04-04
HRP20210143T1 (hr) 2021-03-19
JP7128826B2 (ja) 2022-08-31
AU2018217860B2 (en) 2021-07-08
EP3580211B1 (en) 2020-12-02
CN116554152A (zh) 2023-08-08
CN110678459A (zh) 2020-01-10
LT3580211T (lt) 2021-02-25
US20230121195A1 (en) 2023-04-20
JP2020506946A (ja) 2020-03-05
MA47447A (fr) 2019-12-18
ECSP19057713A (es) 2019-08-30
US20260098036A1 (en) 2026-04-09
UA124507C2 (uk) 2021-09-29
CU24564B1 (es) 2022-01-13
MA47447B1 (fr) 2021-02-26
EP3580211A1 (en) 2019-12-18
CU20190073A7 (es) 2020-03-04
CN116531380B (zh) 2025-11-07
TW201840549A (zh) 2018-11-16
ZA201905902B (en) 2021-05-26
CA3052718A1 (en) 2018-08-16
WO2018146010A1 (en) 2018-08-16
IL268469B (en) 2022-04-01
JOP20190193B1 (ar) 2024-04-18
TWI770113B (zh) 2022-07-11
AU2018217860A1 (en) 2019-08-22
JOP20190193A1 (ar) 2019-08-08
PL3580211T3 (pl) 2021-04-19
SG11201907232XA (en) 2019-09-27
US12522594B2 (en) 2026-01-13
PE20191496A1 (es) 2019-10-21
CY1124484T1 (el) 2022-07-22
ES2847162T3 (es) 2021-08-02
SI3580211T1 (sl) 2021-06-30
RS61401B1 (sr) 2021-02-26
MX2019009571A (es) 2020-01-20
US20240294505A1 (en) 2024-09-05
CL2019002255A1 (es) 2020-01-03
KR20190115460A (ko) 2019-10-11
SA519402422B1 (ar) 2021-11-14
CR20190364A (es) 2019-09-27
UY37606A (es) 2018-09-28
DOP2019000206A (es) 2019-09-30

Similar Documents

Publication Publication Date Title
KR102627266B1 (ko) 암의 치료를 위한 2-헤테로아릴-3-옥소-2,3-디히드로피리다진-4-카르복스아미드
CN109863140B (zh) 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
EP3713926B1 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
EP3713931B1 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
EP3713923B1 (en) 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
HK40097687B (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
HK40097687A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
HK40098354A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
EA037978B1 (ru) 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования
HK40020738B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK40020738A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)